3 results about "Megakaryocytic cell" patented technology

The present application relates to a method for improving the quality of platelets produced in vitro. Specifically, the present inventors provide a platelet culture medium for in vitro culture, which can significantly improve the yield and quality of platelets cultured in vitro by optimizing the ingredients and adding new ingredients. Specifically, the viability of platelets obtained by culturing megakaryocytes in the culture medium of the present application and the proportion of CD42b+ cells are significantly increased, and the number of platelets produced by a single megakaryocyte is also significantly increased. The present application improves the problems of imperfect platelet function and unstable quality in existing in vitro platelet production technology, provides a stable platelet source for clinical transfusion, and has a wide application prospect.

The present invention provides engineered platelets having a chimeric platelet receptor (CPR) with desired target specificity. Furthermore, the engineered platelets may contain cargo that can be released upon platelet activation. In addition, the platelets can be generated in vitro from megakaryocytes engineered to produce non-thrombotic platelets. [Solution] To provide an engineered megakaryocyte or precursor capable of reducing thrombogenic ability and / or producing platelets with reduced thrombogenic ability, comprising the disruption or deletion of at least one gene encoding a protein involved in the recognition of a primary stimulus for thrombosis, one gene encoding a protein involved in the recognition of a secondary mediator for thrombosis, and one gene encoding a protein involved in the release of a secondary mediator for thrombosis.